BioMed Research International

Research Article

Characterization of CD8+ T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)

Table 1

Monitoring the antigen-specific CD8+ T-cell responses in DTH skin biopsies and peripheral blood of melanoma patients participating in DC-therapy clinical trials. Positive responses were scored according to the strength of the immune response. Clinical outcome of the screened patients.
   DTH skin biopsyPeripheral bloodClinical outcome
Patient codeDisease status Injected DCs id/iv (×106 cells)gp100TyrosinaseMAGE-C2MAGE-A3gp100TyrosinaseMAGE-C2MAGE-A3BORPFS (m)OS (m)
72ED65/0————————SD13.619.1
74ED43/0—++———++—SD37.351.5+
75ED45/0—++++—++++++SD9.350.3+
76NED44/0—+———————51.2+51.2+
83ED40/0—++++++++——++PD2.716.8
88ED54/0++++++—+++PD2.717.7
89NED16/0—+++—+*++——45.6+45.6+
92ED31/0—++——++—PD3.417.2
98ED74/0—+++++++—+++PD2.914.1
102ED20/4++++—+++*+CR22.6+22.6+
107ED4/20—+—+—+++PD1.86.4
113ED4/20+++—+++++*+PR17.8+17.8+
116ED4/20————+++*—SD18.3+18.3+
125ED0/24————————CR13.2+13.2+
NED: no evaluable disease; ED: evaluable disease; BOR: best objective response; PFS: progression-free survival; m: months; OS: overall survival.
*Indicates antigen-specific CD8+ T-cell responses that were present before the DC treatment.
—: no detectable response.
+: weak response (<10%).
++: moderate response (10–20%).
+++: strong response (>20%).